SignalXSignalX

ALNY Alnylam Pharmaceuticals

8-K Current Report
Filed: March 4, 2026
Health Care
Pharmaceutical Preparations
Alnylam Pharmaceuticals Overview

Alnylam Pharmaceuticals (ALNY) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 5.02: Departure/Election of Directors or Officers

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

  • • CEO Dr. Greenstreet granted 55,373 target PSUs on March 2, 2026 with face value of $18.0M at $325.07/share
  • • 100% performance-based; minimum threshold $500/share (~54% above grant date price) must be met or award forfeits entirely
+3 more insights

Get deeper insights on Alnylam Pharmaceuticals

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.